Semafore compound up to 97% effective in prostate tumors.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      SEMAFORE Pharmaceuticals Inc.
    • Abstract:
      Reports that cancer therapies developer Semafore Pharmaceuticals Inc. has unveiled data demonstrating the efficacy and safety of its lead PI3-K inhibitor, SF1126, in a pre-clinical xenograft model of prostate cancer. Suggestion that anticancer activity is enhanced when SF1126 is used in combination with Aventis' cancer drug Taxotere; Maximum tolerated dose (MTD) of SF1126; Firm's plan to file an investigational new drug (IND) application and to initiate clinical trials with the compound in the second half of 2005.